CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). [electronic resource]
Producer: 20020927Description: 421-32 p. digitalISSN:- 1535-6108
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Bone Marrow Cells -- enzymology
- Bone Marrow Transplantation
- Enzyme Inhibitors -- pharmacology
- Flow Cytometry
- Humans
- Immunoblotting
- Interleukin-3 -- metabolism
- Leukemia, Myeloid, Acute -- drug therapy
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Mutation
- Phosphorylation
- Piperazines -- pharmacology
- Proto-Oncogene Proteins -- antagonists & inhibitors
- Proto-Oncogene Proteins c-kit -- drug effects
- Quinazolines -- pharmacology
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Receptors, Cell Surface -- antagonists & inhibitors
- Receptors, Platelet-Derived Growth Factor -- antagonists & inhibitors
- Tandem Repeat Sequences
- Transfection
- Tumor Cells, Cultured -- drug effects
- fms-Like Tyrosine Kinase 3
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.